UPCHealthcare · Drug Manufacturers - Specialty & GenericUPC Stock Forecast: Universe Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 1 Aug 2026 — in the lower half.
UPC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Universe Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Volatility (9): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Universe Pharmaceuticals, Inc. — and when they’d sell — is the membership.
UPC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on UPC, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
UPC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Universe Pharmaceuticals, Inc. (UPC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.1×
- Price / book
- 0.0×
- EV / EBITDA
- 9.4×
Cheaper than 96% of US stocks
Cheaper than 91% of US stocks
Cheaper than 41% of US stocks
- Revenue growth (YoY)
- −14.1%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −6.8%
- Net margin
- −20.6%
Higher than 13% of US stocks
Higher than 28% of US stocks
Higher than 15% of US stocks
- Return on equity
- −7.2%
- Return on assets
- −2.7%
- Dividend yield
- —
Higher than 37% of US stocks
Higher than 36% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
UPC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UPC appears on the weeks it earns a place.
Frequently asked questions about UPC stock
How does Ticker Nerd's model rank UPC?
As at 1 Aug 2026, Universe Pharmaceuticals, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
What is the UPC stock forecast for 2030?
No analyst covering Universe Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UPC are extrapolating price history, which says nothing about the business.
What does Universe Pharmaceuticals, Inc. do?
Universe Pharmaceuticals Inc. is a pharmaceutical company that focuses on manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products in China.
About Universe Pharmaceuticals, Inc.
Universe Pharmaceuticals Inc. is a pharmaceutical company that focuses on manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products in China. Its products are designed for elderly consumers and cover areas such as general wellness, chronic condition support, and common cold and flu relief. The company also distributes third-party biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements, allowing it to serve a broader range of healthcare needs through one sales network. Universe Pharmaceuticals Inc. works with pharmaceutical companies, hospitals, clinics, and drugstore chains, giving it a position across both professional healthcare and retail channels. Headquartered in Ji’an, Jiangxi, China, the company plays a niche role in China’s pharmaceutical market by combining in-house traditional medicine products with externally sourced healthcare items.
CEO Mr. Gang Lai · 216 employees · China · https://www.universe-pharmacy.com